Literature DB >> 22804908

Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin.

Krisztina Matúz1, János Mótyán, Mi Li, Alexander Wlodawer, József Tőzsér.   

Abstract

The kinetic properties of two classical inhibitors of aspartic proteases (PRs), pepstatin A and acetyl-pepstatin, were compared in their interactions with HIV-1 and xenotropic murine leukemia virus related virus (XMRV) PRs. Both compounds are substantially weaker inhibitors of XMRV PR than of HIV-1 PR. Previous kinetic and structural studies characterized HIV-1 PR-acetyl-pepstatin and XMRV PR-pepstatin A complexes and suggested dramatically different binding modes. Interaction energies were calculated for the possible binding modes and suggested a strong preference for the one-inhibitor binding mode for HIV-1 PR-acetyl-pepstatin and the two-inhibitor binding mode for XMRV PR-pepstatin A interactions. Comparison of the molecular models suggested that in the case of XMRV PR the relatively unfavorable interactions at S3' and the favorable interactions at S4 and S4' sites with the statine residues may shift the ground state binding towards the two-inhibitor binding mode, whereas the single molecule ground state binding of statines to the HIV-1 PR appear to be more favorable. The preferred single molecular binding to HIV-1 PR allows the formation of the transition state complex, represented by substantially better binding constants. Intriguingly, the crystal structure of the complex of acetyl-pepstatin with XMRV PR has shown a mixed type of binding: the unusual binding mode of two molecules of the inhibitor to the enzyme, in a mode very similar to the previously determined complex with pepstatin A, together with the classical binding mode found for HIV-1 PR. The structure is thus in good agreement with the very similar interaction energies calculated for the two types of binding.
© 2012 The Authors Journal compilation © 2012 FEBS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22804908      PMCID: PMC6290463          DOI: 10.1111/j.1742-4658.2012.08714.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  31 in total

Review 1.  Drug combinations for HIV: what's new?

Authors:  Andrew Scourfield; Laura Waters; Mark Nelson
Journal:  Expert Rev Anti Infect Ther       Date:  2011-11       Impact factor: 5.091

2.  Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Authors:  Mi Li; Alla Gustchina; Krisztina Matúz; Jozsef Tözsér; Sirilak Namwong; Nathan E Goldfarb; Ben M Dunn; Alexander Wlodawer
Journal:  FEBS J       Date:  2011-10-10       Impact factor: 5.542

3.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A.

Authors:  S Seelmeier; H Schmidt; V Turk; K von der Helm
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

4.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

5.  Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.

Authors:  P M Fitzgerald; B M McKeever; J F VanMiddlesworth; J P Springer; J C Heimbach; C T Leu; W K Herber; R A Dixon; P L Darke
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

6.  Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.

Authors:  Anita Fehér; Péter Boross; Tamás Sperka; Gabriella Miklóssy; János Kádas; Péter Bagossi; Stephen Oroszlan; Irene T Weber; József Tözsér
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

7.  Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.

Authors:  S S Hoog; E M Towler; B Zhao; M L Doyle; C Debouck; S S Abdel-Meguid
Journal:  Biochemistry       Date:  1996-08-13       Impact factor: 3.162

8.  In vivo and in vitro autoprocessing of human immunodeficiency virus protease expressed in Escherichia coli.

Authors:  C Z Giam; I Boros
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

Review 9.  The tale of xenotropic murine leukemia virus-related virus.

Authors:  Harriet C T Groom; Kate N Bishop
Journal:  J Gen Virol       Date:  2012-02-22       Impact factor: 3.891

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  5 in total

1.  Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases.

Authors:  János András Mótyán; Márió Miczi; József Tőzsér
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

2.  Biochemical characterization of Ty1 retrotransposon protease.

Authors:  Lívia Diána Gazda; Krisztina Joóné Matúz; Tibor Nagy; János András Mótyán; József Tőzsér
Journal:  PLoS One       Date:  2020-01-09       Impact factor: 3.240

3.  Biochemical Characterization of Human Retroviral-Like Aspartic Protease 1 (ASPRV1).

Authors:  Mária Golda; János András Mótyán; Katalin Nagy; Krisztina Matúz; Tibor Nagy; József Tőzsér
Journal:  Biomolecules       Date:  2020-07-06

Review 4.  Impact of novel microbial secondary metabolites on the pharma industry.

Authors:  Dulce Ramírez-Rendon; Ajit Kumar Passari; Beatriz Ruiz-Villafán; Romina Rodríguez-Sanoja; Sergio Sánchez; Arnold L Demain
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-21       Impact factor: 4.813

5.  Different Mutation Tolerance of Lentiviral (HIV-1) and Deltaretroviral (BLV and HTLV) Protease Precursors.

Authors:  János András Mótyán; Norbert Kassay; Krisztina Matúz; József Tőzsér
Journal:  Viruses       Date:  2022-08-26       Impact factor: 5.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.